Mitochondrial Peptide SS-31 Shields Brain Cells After Cardiac Arrest

Cardiac arrest triggers global brain ischemia, and even successfully resuscitated patients face up to 70% in-hospital mortality from subsequent brain injury. Current options — primarily mild therapeutic hypothermia — are limited and contested, creating an urgent need for new neuroprotective strategies. This study tested whether SS-31, a mitochondria-targeting tetrapeptide that binds cardiolipin and suppresses cytochrome c peroxidase activity, could reduce post-arrest brain injury by targeting microglial ferroptosis and inflammatory polarization.

Using a well-established asphyxia-induced cardiac arrest model in male Sprague-Dawley rats, the team divided resuscitated animals into saline-treated controls, SS-31-treated (30 mg/kg IV), and sham groups. Over 72 hours, SS-31-treated rats showed markedly higher survival rates, better neurological deficit scores, and lower serum NSE and S100B — established markers of neuronal injury. Hippocampal histology confirmed reduced neuronal damage in treated animals. Critically, the researchers observed robust ferroptotic activity in microglia post-arrest, evidenced by GPX4 downregulation, elevated iron and MDA, and reduced GSH and SOD, all of which SS-31 reversed.

Mechanistic experiments used adeno-associated virus vectors with a Cx3cr1 promoter to knock down Sesn2 specifically in microglia. Sesn2 knockdown abolished most of SS-31's protective effects — restoring ferroptosis markers and re-amplifying pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) — confirming Sesn2 as the central mediator. In complementary in vitro work, BV2 microglia subjected to oxygen-glucose deprivation/reoxygenation recapitulated ferroptotic features; SS-31 treatment dose-dependently improved cell viability, reduced lipid peroxidation (C11-BODIPY assay), upregulated GPX4 and SLC7A11, and skewed polarization markers away from iNOS (M1) toward CD206 (M2). Sesn2 siRNA knockdown in BV2 cells similarly negated these benefits.

Together, the data position the Sesn2–GPX4 axis as a druggable node: Sesn2 activation by SS-31 appears to sustain GPX4 function, preventing iron-catalyzed lipid peroxidation and the subsequent inflammatory cascade that amplifies neuronal death. The dual action — limiting microglial death by ferroptosis while simultaneously dampening M1 neuroinflammation — could explain the robust functional and survival benefits observed.

Caveats include the exclusive use of male rats (sex-specific responses remain unexplored), the pharmacological rather than genetic induction of SS-31 effects, and the absence of dose-optimization data. Translation to human cardiac arrest will also need to address delivery timing and the complexity of post-resuscitation care. Nevertheless, SS-31 represents a mechanistically novel and translatable candidate for clinical development in post-cardiac arrest neuroprotection.